NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

CompletedPhase 4

Sponsor: Hoffmann-La Roche

Conditions: Rheumatoid Arthritis

Interventions: rituximab [MabThera/Rituxan], methotrexate, methylprednisolone

Countries: Tunisia

In this open-label single arm study the safety and efficacy of Mabthera will be evaluated in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will receive MabThera (1000mg iv infusion) on days 1 and 15, and background methotrexate (10-25mg po or sc weekly). After the initial study period of 24 weeks, eligible patients may receive up to 3 re-treatments with MabThera. The anticipated time on study treatment is 1-2 years and target sample size is \<50

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* adult patients \>/= 18 years of age
* rheumatoid arthritis DAS28 \>/= 3.2
* receiving treatment on an outpatient basis
* experienced an inadequate response to previous or current treatment with methotrexate

Exclusion Criteria:

* rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA
* history of or current inflammatory joint disease other than RA
* previous treatment with any cell-depleting therapies

Locations (4)

Sousse, Tunisia
Tunis, Tunisia
Tunis, Tunisia
Tunis, Tunisia